Issues related to the implementation of the Medicare Drug Negotiations and the calculation of the Medicaid Rebate and Best Price. issues relating to MFN pricing and other price controls in drugs.
2025 · 4th Quarter (Oct 1 - Dec 31)
AMGEN, INC.
Filed by FEDERAL HEALTH COUNSEL, LLC.
Open official filingSource-reported fields
Filing overview
- Type
- 4th Quarter - Report
- Posted
- Jan 26, 2026
- Income
- Not reported
- Expenses
- Not reported
- Registrant
- FEDERAL HEALTH COUNSEL, LLC
- Client
- AMGEN, INC.
- Filing UUID
- c2534965-4ef1-4fb1-9b7e-8b837578d510
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.